BioMarin Pharmaceutical Inc

BioMarin is headquartered in the United States and sells directly through commercial teams in the U.S., Europe, South America and other significant markets. The company also uses distributors in selected countries, especially outside the U.S., where regulatory approvals and named-patient sales can be handled locally. Its revenue base is global, but the business is exposed to regional ordering patterns, including large government purchases in parts of Latin America and the Middle East. The reports specifically note growth in VOXZOGO across all regions, PALYNZIQ primarily in the U.S., and ROCTAVIAN in the U.S. and Europe. Because the company operates across multiple currencies and healthcare systems, foreign exchange, reimbursement and trade conditions can affect both demand and timing of revenue recognition.

BioMarin faces the typical risks of a rare-disease biotech company: dependence on a small number of products, regulatory and clinical development uncertainty, and heavy reliance on specialized manufacturing and distribution. The company specifically notes that large periodic government orders can cause significant quarter-to-quarter revenue swings, and that generic competition has already reduced KUVAN sales after loss of exclusivity. Its ALDURAZYME business depends on Sanofi, so any disruption to that manufacturing, marketing and sales agreement would materially affect the product. Supply chain interruptions, raw material inflation, tariffs, geopolitical instability and foreign exchange volatility can also affect global operations because the company sells and manufactures across multiple regions. As with other biopharma companies, patent disputes, reimbursement changes, adverse clinical data, cybersecurity incidents and regulatory actions could all pressure revenue, margins and pipeline value.